Abstract 160P
Background
Lung cancer (LC) screening has been shown to be effective to reduce specific mortality in at-risk populations but its performances could be improved by using non-invasive biomarkers such as the analysis of volatile organic compounds (VOCs) in exhaled air from screened subjects. Some limited studies suggest that VOCs could be used to detect LC patients (LCP). Our project aims at determining which VOCs profile could be used to differentiate LCP from healthy controls (HC) in a much larger series of cases.
Methods
We planned to recruit LCP (n = 750) in 7 different thoracic oncology departments, and HC (n = 750) from a preventive health centre. Subjects’ exposure was not monitored before VOC collection in order to reproduce real-life conditions. VOCs were collected using the Reciva® mask (Owlstone Medical Ltd.) in sorbents. VOCs were determined using GC-MS analysis. Classification of VOCs was performed using white box auto-ML methods adapted for unbalanced data (Scikit learn + Ripper).
Results
Preliminary analyses on the first 295 LCP and 713 HC found that 2 VOCs rulesets are able to differentiate LCP from HC with 67.8% sensitivity associated with 100% confidence (or for a sensitivity of 84.7%, confidence decreased to 92.6%).
Conclusions
This largest series to date in the literature showed that non-invasive analysis of VOCs in exhaled air could distinguish LCP from HC, and may improve the effectiveness of LC screening. A larger study to validate this new “fingerprint” in a LC screening routine process is planned.
Clinical trial identification
CATOCOV: NCT03250390, PATHACOV: InterReg France Wallonie Vlaanderen, project 1.1.297.
Legal entity responsible for the study
CHU de Lille.
Funding
PATHACOV: InterReg France Wallonie Vlaanderen, CATOCOV: French Ministry of Health/GIRCI Nord Ouest.
Disclosure
R. Matran: Financial Interests, Institutional, Invited Speaker: Novartis. A. Scherpereel: Financial Interests, Institutional, Research Grant: Amphera, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Epizyme, MSD, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Boehringer Ingelheim, MSD, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, MSD, BMS. All other authors have declared no conflicts of interest.